Internationally Recognized Cancer Survivorship Leader Dr. Nicole Stout Joins ImpediMed as Chief Clinical Innovation Officer

Pioneer of prospective surveillance brings more than 25 years of research, health system implementation, policy leadership and clinical business experience to accelerate adoption of the SOZO^® platform in cancer survivorship care pathways

CARLSBAD, Calif., Oct. 27, 2026 /PRNewswire/ -- ImpediMed, a leader in medical technologies for clinically monitoring fluid status and body composition, today announced that Nicole L. Stout, DPT, CLT-LANA, FAPTA, will join the company as Chief Clinical Innovation Officer, effective November 1, 2026. Dr. Stout will lead clinical strategy, research, medical affairs, and key opinion leader engagement, with a focus on accelerating the adoption of the SOZO^® Digital Health Platform across care settings.

An internationally recognized authority in cancer rehabilitation and survivorship, Dr. Stout has spent more than 25 years helping oncology teams identify treatment-related complications early and intervene before they become disabling. She pairs that scientific record with years of experience putting new care models into practice inside health systems.

From Evidence to Clinical Practice
Dr. Stout's pioneering research helped establish the evidence base for the Prospective Surveillance Model (PSM). The approach pairs pretreatment baseline assessments with risk-stratified interval monitoring, then refers patients to supportive care when changes appear, so care teams can address the physical and functional effects of cancer and its treatment throughout the care continuum.

Dr. Stout has designed and implemented surveillance pathways in health systems, resulting in shortened time to intervention for cancer treatment-related conditions and improved clinical operations and service-line performance. She has won support from executive and clinical leaders, then built the business and operational plans that turn new care models into lasting programs.

Most recently, as Senior Director of Survivorship and Wellness at the American Cancer Society, Dr. Stout led a national portfolio of programs and initiatives addressing supportive care needs across the cancer continuum. Her earlier clinical, research, and leadership experience includes roles at the West Virginia University Cancer Institute and the NIH Clinical Center. She has also led strategic initiatives involving the National Institutes of Health and the World Health Organization and has published more than 100 peer-reviewed and invited articles on survivorship care delivery.

Scaling Prospective Surveillance with SOZO
At ImpediMed, Dr. Stout will guide clinical strategies that help health systems accelerate the use of the SOZO Digital Health Platform across the oncology enterprise. The platform is already established in lymphedema assessment. The National Accreditation Program for Breast Centers (NAPBC) Optimal Resources for Breast Care 2027 standards also name bioimpedance spectroscopy (BIS) as a method that meets Standard 5.8, its new lymphedema assessment requirement. In August of 2026, ImpediMed received FDA 510(k) clearance for sarcopenia risk assessment, enabling care teams to use the same scan to monitor muscle loss. Together, they give health systems a foundation for surveillance programs that extend across cancer types and treatment settings.

"Nicole brings a rare combination of scientific leadership and a proven ability to translate innovation into clinical practice," said Erik Anderson, Managing Director and Chief Executive Officer of ImpediMed. "She has built surveillance programs, navigated complex health system operations, influenced policy, and earned the trust of leaders across the oncology space for over 25 years. At the top of her career, Nicole is choosing to join this team to help define the next chapter of growth for this company, bringing all of her experience to drive SOZO as a standard of care for cancer survivorship. We couldn't be more excited to welcome Nicole to the team."

"I am thrilled to be joining the team at this time. The evidence for early, proactive supportive care is compelling, but real impact depends on what health systems can consistently deliver," said Dr. Stout. "My career has focused on making prospective surveillance practical by connecting objective assessment with clinical workflows, timely intervention, and measurable outcomes. I have been following the SOZO platform and BIS technology over many years, and now is the time to bring together this platform along with my expertise in clinical evidence and implementation to help oncology teams adopt sustainable models of care in cancer survivorship programs."

About ImpediMed
ImpediMed is a global medical technology company that designs and manufactures bioimpedance spectroscopy (BIS) devices, providing clinicians with real-time insights for personalized patient care. The company's SOZO® Digital Health Platform using BIS technology supports noninvasive assessment of fluid status and tissue composition, including applications in cancer-related lymphedema surveillance and sarcopenia risk assessment. The platform also supports structured cancer survivorship and medical weight-management care pathways. For more information, visit www.impedimed.com.

Press Contact:
Jodi Perkins
Supreme Communications, on behalf of ImpediMed
[email protected]

SOURCE ImpediMed